Thorlef Spickschen, Director at Clovis Oncology, Inc. (CLVS), bought 8,600 shares at $5.67 ($49K) on 2019-08-16, disclosed to the SEC on 2019-08-16.
Open-market purchase of $49k CLVS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| CLVS | SELL | 2018-03-09 | $277K | — | Filing → |
| CLVS | SELL | 2018-02-23 | $270K | — | Filing → |
| CLVS | SELL | 2018-01-09 | $292K | — | Filing → |